高级检索
当前位置: 首页 > 详情页

Study on the Anti-inflammatory Activity of N-(E)-p-Coumaroyl Tyrosine In Vitro and In Vivo

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE

机构: [1]Guangdong Pharmaceut Univ, Guangdong Prov Key Lab Adv Drug Delivery Syst, Guangzhou, Peoples R China [2]Guangdong Pharmaceut Univ, Ctr Drug Res & Dev, Guangzhou, Peoples R China [3]Guangdong Pharmaceut Univ, Guangdong Engn & Technol Res Ctr Top Precise Drug, Guangzhou, Peoples R China [4]Guangdong Prov Hosp Occupat Dis Prevent & Treatmen, Guangzhou, Peoples R China [5]Guangdong Prov Hosp Tradit Chinese Med, Dept Orthoped, Guangzhou, Peoples R China [6]Jinan Univ, Guangzhou, Peoples R China
出处:
ISSN:

关键词: Anti-inflammation N-(E)-p-Coumaroyl tyrosine LPS RAW 264 7 macrophages Zebrafish

摘要:
N-(E)-p-Coumaroyl tyrosine is a phenolic amino acid derivative extracted from the Abrus mollis Hance, Syn of Abrus melanospermus subsp. melanospermus, Fabaceae, which has anti-inflammatory activity. In this study, we aimed to investigate the inflammatory activity and mechanism of N-(E)-p-coumaroyl tyrosine by establishing a lipopolysaccharide-stimulated RAW 264.7 cells in vitro and an injured zebrafish tail fin in vivo. The results showed that N-(E)-p-coumaroyl tyrosine decreased the levels of ROS, NO, IL-6, IL-1 beta, and IL-18 secreted by LPS-induced RAW 264.7 macrophages. In addition, the results of in vivo studies showed that it inhibited the aggregation of neutrophils and macrophages to the tail after tail cutting stimulation. In summary, N-(E)-p-coumaroyl tyrosine inhibited the production of NO and ROS; decreased the secretions of IL-6, IL-1 beta, and IL-18; and reduced the aggregation of zebrafish neutrophils and macrophages. Therefore, N-(E)-p-coumaroyl tyrosine may be developed as a potential therapeutic option for inflammatory diseases.

基金:
语种:
WOS:
中科院(CAS)分区:
出版当年[2022]版:
大类 | 4 区 医学
小类 | 4 区 药学 4 区 药物化学
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 药物化学 4 区 药学
JCR分区:
出版当年[2021]版:
Q3 PHARMACOLOGY & PHARMACY Q4 CHEMISTRY, MEDICINAL
最新[2023]版:
Q4 CHEMISTRY, MEDICINAL Q4 PHARMACOLOGY & PHARMACY

影响因子: 最新[2023版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者:
第一作者机构: [1]Guangdong Pharmaceut Univ, Guangdong Prov Key Lab Adv Drug Delivery Syst, Guangzhou, Peoples R China [2]Guangdong Pharmaceut Univ, Ctr Drug Res & Dev, Guangzhou, Peoples R China [3]Guangdong Pharmaceut Univ, Guangdong Engn & Technol Res Ctr Top Precise Drug, Guangzhou, Peoples R China [4]Guangdong Prov Hosp Occupat Dis Prevent & Treatmen, Guangzhou, Peoples R China
共同第一作者:
通讯作者:
通讯机构: [1]Guangdong Pharmaceut Univ, Guangdong Prov Key Lab Adv Drug Delivery Syst, Guangzhou, Peoples R China [2]Guangdong Pharmaceut Univ, Ctr Drug Res & Dev, Guangzhou, Peoples R China [3]Guangdong Pharmaceut Univ, Guangdong Engn & Technol Res Ctr Top Precise Drug, Guangzhou, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:2018 今日访问量:0 总访问量:645 更新日期:2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持:重庆聚合科技有限公司 地址:广州市越秀区大德路111号